文献速递中枢神经肿瘤放疗

老年胶质母细胞瘤短程放疗生存结局:随机3期试验亚组分析

Survival Outcomes With Short-Course Radiation Therapy in Elderly Patients With Glioblastoma: Data From a Randomized Phase 3 Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-03-30

该研究对一项随机3期非劣效试验中≥65岁胶质母细胞瘤患者进行亚组分析,比较25 Gy/5次短程放疗与40 Gy/15次常用放疗的生存结局。结果显示两组中位总生存期(6.8个月 vs 6.2个月,P=.936)和中位无进展生存期(4.3个月 vs 3.2个月,P=.706)均无统计学显著差异。结论认为25 Gy/5次短程放疗是≥65岁患者的可接受治疗选择。

要点

  • ≥65岁胶质母细胞瘤患者中,25 Gy/5次与40 Gy/15次放疗的总生存期无显著差异。
  • 两组中位总生存期分别为6.8个月和6.2个月(P=.936),中位无进展生存期分别为4.3个月和3.2个月(P=.706)。
  • 25 Gy/5次短程放疗可作为≥65岁、体能状态差或化疗禁忌患者的可接受选择。

核心结论

  • 在≥65岁胶质母细胞瘤患者中,短程放疗(25 Gy/5次)与常用放疗(40 Gy/15次)的生存结果无统计学显著差异。
  • 25 Gy/5次短程放疗是≥65岁患者的可接受治疗选择,主要用于体能状态差或存在化疗禁忌者。

研究设计与样本

  • 原始试验为3期、随机、多中心、前瞻性、非劣效试验,纳入老年和/或虚弱胶质母细胞瘤患者。
  • 患者按1:1随机分配至短程放疗组(25 Gy/5次,臂1)或常用放疗组(40 Gy/15次,臂2),并按年龄(<65岁和≥65岁)、KPS和手术范围分层。
  • 本次亚组分析仅评估≥65岁患者,从初始98例患者中纳入61例,其中臂1为26例,臂2为35例。

主要发现

  • 臂1中位总生存期为6.8个月(95%CI 4.5-9.1个月),臂2为6.2个月(95%CI 4.7-7.7个月),P=.936。
  • 臂1中位无进展生存期为4.3个月(95%CI 2.6-5.9个月),臂2为3.2个月(95%CI 0.1-6.3个月),P=.706。

关键数值与推荐

  • 老年虚弱患者定义为年龄≥65岁且KPS为50%-70%;老年非虚弱患者定义为年龄≥65岁且KPS为80%-100%。

临床怎么用

  • 对于≥65岁胶质母细胞瘤患者,尤其是体能状态差或化疗禁忌者,可考虑采用25 Gy/5次的短程放疗方案。

局限性

  • 该分析为未计划的亚组分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To perform a subset analysis of survival outcomes in elderly patients with glioblastoma from a randomized phase 3 trial comparing 2 short-course radiation therapy (RT) regimens in elderly and/or frail patients. METHODS AND MATERIALS: The original trial population included elderly and/or frail patients with a diagnosis of glioblastoma. Patients joined the phase 3, randomized, multicenter, prospective, noninferiority trial; were assigned to 1 of 2 groups in a 1:1 ratio, either short-course RT (25 Gy in 5 fractions, arm 1) or commonly used RT (40 Gy in 15 fractions, arm 2); and were stratified by age (<65 years and ≥65 years), Karnofsky Performance Status (KPS), and extent of surgery. For the subset analysis in this study, only patients aged ≥65 years were evaluated (elderly and frail patients were defined as patients aged ≥65 years with KPS of 50%-70%; elderly and non-frail patients were defined as patients aged ≥65 years with KPS of 80%-100%); 61 of the 98 initial patients comprised the patient population, with 26 patients randomized to arm 1 and 35 to arm 2. RESULTS: In this unplanned analysis, the short-course RT results were not statistically significantly different from the results of commonly used RT in elderly patients. The median overall survival time was 6.8 months (95% confidence interval [CI], 4.5-9.1 months) in arm 1 and 6.2 months (95% CI, 4.7-7.7 months) in arm 2 (P=.936). The median progression-free survival time was 4.3 months (95% CI, 2.6-5.9 months) in arm 1 and 3.2 months (95% CI, 0.1-6.3 months) in arm 2 (P=.706). CONCLUSIONS: A short-course RT regimen of 25 Gy in 5 fractions is an acceptable treatment option for patients aged ≥65 years, mainly those with a poor performance status or contraindication to chemotherapy, which would be indicated in cases of methylated O6 methylguanine-DNA-methyltransferase promoter tumors.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Guedes de Castro D, Matiello J, Roa W, et al. Survival Outcomes With Short-Course Radiation Therapy in Elderly Patients With Glioblastoma: Data From a Randomized Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2017. PMID: 28602417. doi:10.1016/j.ijrobp.2017.03.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。